HACEK Bacteria, Heart Valves, and Your Saliva: An Honest Read

If you've looked at your Oravi panel and Googled bacteria like Haemophilus parainfluenzae or Cardiobacterium hominis, you've probably encountered the term "HACEK." And if you went a few links deep, the results may have looked alarming — "bacteria that cause heart valve infections," "endocarditis pathogens," and so on.

Here's an honest read of what HACEK is, what it isn't, and what actually matters for the people for whom it does matter.

What HACEK is

HACEK is a clinical acronym that names five bacterial groups, all of which can — rarely — cause a specific kind of heart infection called infective endocarditis (infection of the heart valves). The five are:

• H — Haemophilus (specifically H. parainfluenzae)
• A — Aggregatibacter (mainly A. actinomycetemcomitans)
• C — Cardiobacterium (C. hominis and C. valvarum)
• E — Eikenella (E. corrodens)
• K — Kingella (K. kingae, though K. oralis is the common oral one)

The acronym was coined in the 1960s and has been used in clinical microbiology ever since. It's primarily useful for cardiologists and infectious disease specialists who are treating someone with a confirmed heart valve infection — it tells them which family of bacteria they're dealing with and what antibiotics will work.

For everyone else, HACEK is mostly a label without much practical relevance.

Why this is mostly not a concern for most people

Three facts matter here:

HACEK endocarditis is rare. Across all infective endocarditis cases — itself an uncommon condition — HACEK organisms account for about 3% of cases. The population incidence is roughly 0.15 to 0.30 cases per 100,000 people per year. In a city of one million, that's 1.5 to 3 cases per year from all five HACEK groups combined.

These bacteria live in healthy mouths. Cardiobacterium hominis, for example, is carried by an estimated 68% of healthy adults — more than two-thirds of the general adult population. Haemophilus parainfluenzae is one of the most common bacteria in healthy saliva, typically representing 2-15% of total oral bacteria. If having these bacteria caused heart valve infections, we'd be facing a public health crisis. We're not.

Almost all HACEK endocarditis happens to people with pre-existing valve abnormalities. Congenital heart defects, prosthetic (replacement) heart valves, prior heart valve infections, or other forms of structural valve disease. The pathway requires the bacterium to enter the bloodstream and then seed a damaged valve. In someone with structurally normal valves, the immune system clears the bacteremia without consequence. In someone with valve damage, that bacteremia can lodge on the damaged surface and start an infection.

The bacteria, in other words, are not the problem. The problem is what happens when those bacteria meet a damaged valve. Most of us have routine bacteremia events many times a week from brushing, flossing, chewing — and our bodies handle them silently. The same biology that's benign in 95%+ of adults becomes dangerous in the much smaller population with valve damage.

What does matter: oral hygiene

The most useful evidence on preventing endocarditis isn't about targeting any specific organism. It's about overall oral hygiene.

A 2023 case-control study compared 181 patients who had developed infective endocarditis to a matched group of patients who had similar valve disease but had not developed endocarditis. The differences they found were striking:

• The endocarditis group had 53% more dental calculus (tartar) than the controls
• They had 26% more dental plaque
• They reported significantly fewer dental visits
• Common oral bacteria were found in the blood cultures of 44% of endocarditis cases

This is the kind of finding that turns the HACEK story from "scary microbiology" into "boring but real oral hygiene matters." The mechanism is intuitive: more calculus and plaque mean more biofilm, which means more frequent and higher-magnitude bacteremia events during normal mouth activity (brushing, eating, even just talking). For people with healthy valves, that doesn't matter. For people with damaged valves, it accumulates risk.

This matches what the 2025 American Heart Association Scientific Statement on periodontal disease and cardiovascular disease recommends. The core nonsurgical interventions for managing oral-related cardiovascular risk are well-established and not exotic:

• Oral hygiene instruction
• Professional cleanings (scaling and root planing)
• Antibiotics when clinically indicated

Nothing about microbiome panels appears in the recommended pathway. The AHA's position, in plain terms, is that the standard dental care you should already be doing is also the right approach for managing endocarditis risk.

If you have a known heart valve condition

For a defined high-risk group, the picture is different — and well-managed by existing clinical guidelines.

The AHA defines several conditions as putting someone in the high-risk category for infective endocarditis:

• A prosthetic (replacement) heart valve, including transcatheter and homograft valves
• Prior history of infective endocarditis
• Certain congenital heart defects (especially unrepaired or partially repaired cyanotic conditions)
• Cardiac transplant recipients with valvulopathy

For people in these categories, the standard clinical approach to HACEK risk is:

Excellent routine oral hygiene — the Lockhart 2023 finding above is the strongest argument. Calculus and plaque matter more than which specific bacteria are present.

Antibiotic prophylaxis before certain dental procedures — typically a single dose of amoxicillin (or clindamycin/azithromycin for penicillin-allergic patients) about an hour before procedures that involve manipulation of gingival tissue or the periapical region of teeth. Your cardiologist and dentist coordinate this; you don't need to manage it from a microbiome panel.

Regular professional dental care — both for the cleaning itself and for the opportunity for your dentist to assess any developing issues before they become bacteremia-prone.

What is not in the recommended pathway: microbiome-guided antimicrobial mouthwashes, organism-specific suppression strategies, or using saliva tests as endocarditis screening tools. These approaches have no evidence base for endocarditis prevention.

What about mouthwashes?

A reasonable question, given that HACEK bacteria are in your mouth and antiseptic mouthwashes kill mouth bacteria. The honest answer: this is more complicated than it sounds.

A 2026 study compared four antiseptic mouthwash formulations against gram-negative oral bacteria (the HACEK group is mostly gram-negative). The findings:

• Octenidine showed the strongest activity against gram-negative bacteria
• Chlorhexidine — the traditional "gold standard" — was effective against gram-positive bacteria but markedly less effective against gram-negative ones
• CPC and PHMB fell between

This matters because the HACEK bacteria are gram-negative, so chlorhexidine — the mouthwash people most commonly reach for when they want to "really clean" their mouth — isn't actually well-targeted for HACEK reduction.

But the bigger question is whether routinely reducing HACEK bacteria with mouthwash makes any clinical sense. The evidence doesn't support it:

• For healthy people, there's no benefit to reducing commensal HACEK bacteria. Daily antiseptic mouthwash also depletes the helpful nitrate-reducing community (Rothia, Neisseria), which is linked to higher blood pressure in observational studies.
• For people at high risk for endocarditis, antibiotic prophylaxis before procedures is the evidence-based approach. Daily antiseptic mouthwash hasn't replaced this in any major guideline.

In other words: even if octenidine works better than chlorhexidine for gram-negative bacteria in a lab dish, that's not a reason to add it to your routine. The actionable interventions are the ones the AHA already recommends.

What your panel is and isn't telling you

Seeing Haemophilus parainfluenzae, Cardiobacterium hominis, or other HACEK bacteria on your Oravi panel is unremarkable. Most healthy adults will have at least one of them at detectable levels. Detection alone is not a signal — these bacteria are routine residents.

What your panel can meaningfully tell you about endocarditis-relevant biology is more about the broader oral community than any specific HACEK organism. Things like:

• Overall dysbiosis patterns — are your gum-disease-associated bacteria elevated? Is your commensal community depleted? These are the patterns that suggest the kind of oral inflammation that drives bacteremia frequency.
• Periodontal disease bacteria — Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, Fusobacterium. These are the bacteria most strongly linked to periodontal disease, which is the underlying mechanism connecting oral and cardiovascular health. If those are elevated, your gum tissue is likely actively inflamed, which makes bacteremia events more frequent and more severe.

This is the more productive read of the panel. The HACEK bacteria themselves are mostly noise; the dysbiosis context is the signal.

The bottom line

For most people, seeing HACEK bacteria on a saliva panel is the equivalent of seeing your house cat on a list of "felines capable of injury." Technically true, almost never relevant. The bacteria are routine oral residents; the disease they're associated with is rare and primarily affects a defined high-risk group; and even for that group, the right response is well-established clinical care, not microbiome management.

If you don't have heart valve disease, this isn't something to worry about.

If you do, your cardiologist and dentist are the right resources, and they already have a plan for this.

In either case, the highest-leverage intervention is the most ordinary one: brush twice a day, floss daily, see your dentist regularly. That's the action item that the strongest endocarditis-prevention evidence actually supports.

---

Sources

1. Lockhart PB, Chu V, Zhao J, et al. Oral hygiene and infective endocarditis: a case control study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2023;136(3):333-342.
2. Tran AH, Zaidi AH, Bolger AF, et al. Periodontal disease and atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2025.
3. Malani AN, Aronoff DM, Bradley SF, Kauffman CA. Cardiobacterium hominis endocarditis: two cases and a review of the literature. European Journal of Clinical Microbiology & Infectious Diseases. 2006;25(9):587-95.
4. Coburn B, Toye B, Rawte P, et al. Antimicrobial susceptibilities of clinical isolates of HACEK organisms. Antimicrobial Agents and Chemotherapy. 2013;57(4):1989-91.
5. Korbecka-Paczkowska M, Paczkowska-Walendowska M, Cielecka-Piontek J, Karpiński TM. Antiseptic mouthwashes as a potential strategy for controlling oral dysbiosis: antimicrobial effect against opportunistic pathogens. Journal of Dentistry. 2026.
6. Revest M, Egmann G, Cattoir V, Tattevin P. HACEK endocarditis: state-of-the-art. Expert Review of Anti-Infective Therapy. 2016;14(5):523-30.